Key facts
- BiomeBank’s last known valuation is $70.0M (Apr 2026).
- It has raised $42.7M; the latest was Later Stage VC ($10.0M) in Apr 2026.
- Notable investors include Ellerston Capital, Blackmores, Innovative Manufacturing Cooperative Research Centre, South Australian Venture Capital Fund, The Hospital Research Foundation.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for BiomeBank
- ·The full record, as it builds
Funding rounds
No funding rounds for BiomeBank are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BiomeBank
Operator of a biotechnology company intended to facilitate microbial therapies. The company uses a unique combination of machine learning and microbiology to identify bacterial strains that influence disease and is developing a pipeline of microbiome therapies, enabling doctors to treat and prevent disease by restoring gut microbial ecology.
- Sector
- Healthcare
- HQ
- Adelaide, Australia
- Founded
- 2016
- Employees
- 37
- Website
- biomebank.com/
- Ownership
- Privately Held (backing)
BiomeBank doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BiomeBank shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BiomeBank in its N-PORT filings yet. We sweep new filings monthly.